Programme

DRAFT PROGRAMME - Timings and content subject to change

09:00 – 09:10	Welcome to BOOS 2020
09:10 – 10:00	Paper Session 1 (BOOS & MBD)
09:10 – 09:18	Megan Scotcher - Sonographic standards in Musculoskeletal Oncology - BOOS collaborative study
09:18 – 09:26	Raja Bhaskara Rajasekaran - Was it safe to perform surgery on bone and soft tissue tumours during the COVID-19 pandemic? – Results from the multicentre BOOS (British Orthopaedic Oncology Society) observational study
09:26 – 09:34	Katie Hoban - MIRELS’ SCORE – IS IT VALID IN UPPER LIMB BONY METASTASES?
09:34 – 09:42	Rhys Morris - Bone Biopsy Results in Patients with a History of Malignancy: A Case Series of 378 patients
09:42 – 09:50	Samantha Downie - Development and testing of a novel set of quality indicators (QIs) of care for patients with metastatic bone disease (MBD)
09:50 – 10:00	Session Q&A
10:05 – 10:25	Keynote Speaker - Prof Rob Ashford, President BOOS. “An update on metastatic bone disease”
10:30 – 11:10	Paper Session 2 (Pathways and Outcomes) SPONSORED BY: ADLER ORTHO
10:30 – 10:38	Muhammad Adeel Akhtar - Osseointegrated Reconstruction for Lower Limb Amputees Following Treatment of Tumours
10:38 – 10:46	Raashad Hasan - An evaluation of the quality of life and functional outcomes of patients undergoing through knee and transfemoral amputation as children in the Royal National Orthopaedic Hospital service
10:46 – 10:54	Danielle Maes - Is it safe to omit a bone scintigraphy from the initial work up of conventional chondrosarcoma?
11:54 – 11:02	Victoria Vinader - Bone Cancer Awareness Initiative- Saving Lives Through Earlier Diagnosis
11:02 – 11:10	Session Q&A
11:10 – 11:30	Morning Break - poster viewing, product demos STRYKER LAUNCH PAD
11:35 – 11:55	Keynote Speaker - Dr Fernanda Amary, RNOH “Translating 100,000 Genomes into clinical practice”
12:00 – 13:00	Paper Session 3 (Soft Tissue Sarcoma) SPONSORED BY IMPLANTCAST
12:00 – 12:08	Jonathan Perera - Intermuscular localised myxoid liposarcoma can be managed with marginal resection if used with neoadjuvant radiotherapy
12:08 – 12:16	Nima Razii - Closed incision negative pressure wound therapy (NPWT) versus conventional dressings following soft tissue sarcoma excision: a prospective, randomised controlled feasibility trial
12:16 – 12:24	Kenneth Rankin - Fluorescence guided surgery for sarcoma resection- world's first case series
12:24 – 12:32	Rebecca Morgan - A case series of over 350 Schwannomata – the Royal National Orthopaedic Hospital’s experience (2017-2020)
12:32 – 12:40	Sudhir Kannan - Predictors of survival local recurrence and metastases of Leiomyosarcomas of trunk wall and extremities: a retrospective study.
12:40 – 12:48	Omar El-Omar - Value of Drains in Soft Tissue Tumour Surgery – Specialist Regional Service Experience
12:48 – 13:00	Session Q&A
13:00 – 13:30	Lunch - poster viewing, product demos IMPLANTCAST LAUNCH PAD ADLER ORTHO LAUNCH PAD
13:35 – 13:55	Keynote Speaker - Dr Michiel Van de Sande, Leiden. “Collaboration and the evolution of PERSARC”
14:00 – 14:50	Paper Session 4 (Pelvis) SPONSORED BY: 3D LIFEPRINTS
14:00 – 14:08	Vineet Kurisunkal - Is 2mm an achievable safe wide margin in high-grade conventional chondrosarcomas of the pelvis?
14:08 – 14:16	Vineet Kurisunkal - Does Navigation Assisted Tumour Surgery Improve Margins in Pelvic Chondrosarcomas?
14:16 – 14:24	Viswanath Jayasankar - Do mainstream prognostic scores reliably predict complication rates in patients undergoing pelvic/femoral resection and reconstruction for bone tumours?
14:24 – 14:32	M ATHER SIDDIQI - Custom 3D printed cutting Jigs for Pelvic Bone Tumour Resections. A Single Centre Experience of 12 cases
14:32 – 14:40	M ATHER SIDDIQI - Off the Rack Reconstruction Solution With TMARS for Periacetabular Pelvic Resections – An Experience Of 20 Cases At A High Volume Referral Center
14:40 – 14:50	Session Q&A
14:55 – 15:15	Keynote Speaker - Prof Tim Briggs CBE, RNOH “GIRFT and Cancer”
15:15 – 15:35	Afternoon break - poster viewing, product demos 3D LIFEPRINTS LAUNCH PAD
15:40 – 16:00	Interactive Extreme Orthopaedic Symposium. Hosted by Mr Will Aston, Stanmore SPONSORED BY STRYKER
16:05 – 17:05	Paper Session 5 (EPR)
16:05 – 16:13	Danielle Maes - Does a fast-resorbable, antibacterial-loaded hydrogel coating reduce the rate of early periprosthetic infection following endoprosthetic reconstruction following oncological resection?
16:13 – 16:21	Smriti Kapoor - Predicting length of stay for proximal femoral endoprosthetic replacements for bone tumours
16:21 – 16:29	Raja Bhaskara Rajasekaran - Augmenting Osteointegration of Proximal Femoral Endoprosthesis Using Porous Titanium Bridging Endosteal Collars – a preliminary case series
16:29 – 16:37	Federico Sacchetti - Endoprosthetic replacement of the proximal tibia for oncological conditions
16:37 – 16:45	Rohit Dhawan - Distal Femoral Replacement- does length matter?
16:45 – 16:53	Catrin Wigley - Long term Outcomes of Proximal femoral Replacements with or without acetabuloplasty
16:53 – 17:05	Session Q&A
17:05 – 17:20	Closing remarks and prize giving
17:20 – 17:35	BOOS AGM
17:40	End of conference

The BOOS Conference has been awarded up to 6 CPD points by The Royal College of Surgeons of England

Keynote Speakers

Dr Fernanda Amary, RNOH

Dr Fernanda Amary trained and worked as a pathologist and associate professor of pathology in Sao Paulo, Brazil until 2009. She completed her MPhil (2001) and PhD (2007) with focus in molecular genetics of sarcomas.

In 2010 she moved to the UK to take a post as a specialist bone and soft tissue histopathologist at the Royal National Orthopaedic Hospital. She is a full-time Consultant bone and soft tissue pathologist, Clinical Lead for Molecular Pathology and Honorary Associate Professor at University College London Cancer Institute.

Her research focus is in molecular genetic markers for these tumours. She has developed and maintains a teaching application for mobile devices on bone and soft tissue tumour with over 950 annotated images and 10000 users worldwide.

Dr Michiel A.J. Van de Sande, Leiden University Medical Centre

Michiel van de Sande currently works as a senior (paediatric) Orthopaedic Surgeon in the Leiden University Medical Center (LUMC) and the Princes Maxima Center for paediatric oncology in Utrecht where he surgically treats paediatric, AYA and adult patients with bone and soft tissue tumours. He started in Leiden in 2010 as an Senior Orthopaedic Surgeon, immediately after completing his Orthopaedic training that was followed by a fellowship in paediatric Orthopaedic oncology at the Nuffield Orthopaedic Centre in Oxford.

His surgical Speciality focuses on the treatment of paediatric, AYA and adult patients with Bone and soft tissue sarcomas and paediatric orthopaedics (oncology and limb reconstruction).

His scientific activity started with the design of (inter)national sarcoma databases and registrations. Research lines have been set up in recent years which have an international collaborative basis, such as multicenter studies on giant cell tumours of the joint and bone, soft tissue sarcomas, chondrosarcomas, adamantinoma, Osteo- and Ewing Sarcoma. The Personalised Sarcoma Care project aims to support patients and multidisciplinary teams with up to date information on prognosis now and in the long term, in order to personalise in clinical decision making for both treatment and follow-up of sarcoma patients. He has published more than 100 peer reviewed papers and book-chapters; His research was funded by several scientific grants; e.g. the Dutch Cancer Fund (KWF), Alpe-D’huzes and Team Westland.

Prof Tim Briggs CBE, RNOH

Tim was appointed to the Royal National Orthopaedic Hospital as Consultant in 1992. His specialist interests are in orthopaedic oncology as well as surgery to the hip and knee. He was Medical Director at the RNOH for 15 years, ensuring a re-build and was President of the British Orthopaedic Association in 2014.

He was appointed as National Director for Clinical Quality and Efficiency for the NHS in September 2015 and has been asked to lead and roll out his GIRFT methodology, developed in orthopaedics, across all surgical and medical specialities within the provider network. In January 2019, he was made National Director of Clinical Improvement for the NHS.

Professor Briggs was made a Commander of the Most Excellent Order of the British Empire (CBE) in the 2018 New Year’s Honours List for services to the surgical profession.

Prof Robert U. Ashford, University Hospitals of Leicester

Rob was appointed at Leicester as a Consultant Orthopaedic & Musculoskeletal Tumour Surgeon in 2008, working jointly at Nottingham University Hospitals, following fellowships in Sydney and at the RNOH. He is the lead clinician of the East Midlands Sarcoma Service. He clinical practice is orthopaedic oncology and lower limb arthroplasty.

His research interests are metastatic bone disease, palliative orthopaedic surgery, genetics of soft tissue sarcoma and outcome measures in sarcoma. He was co-chair of the BOOS working party on surgical management of metastatic bone disease.

He was chosen as an ABC travelling fellow in 2014 and in 2019 he was both promoted to Honorary Professor at the Leicester Cancer Research Centre and elected President of the British Orthopaedic Oncology Society. He is grateful that Saracens have ensured Leicester Tigers have avoided relegation

Questions & discussion